The phase II study: some reflections, particularly concerning disseminated breast cancer.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002330:Carmustine / Q000627:therapeutic use; D003510:Cyclohexanes; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008937:Mitomycins / Q000009:adverse effects; D009362:Neoplasm Metastasis / Q000188:drug therapy*; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use
D000970:Antineoplastic Agents; D003510:Cyclohexanes; D008937:Mitomycins; D009607:Nitrosourea Compounds; D003520:Cyclophosphamide; D005472:Fluorouracil; D002330:Carmustine; D011241:Prednisone